/
MEDIF
$0.05-$0.00 (-1.89%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.04 – $0.08
31% from low
Exchange
OTC Link
OS
Borrow rate
3.31%
Moderate
Price (6 mo)
Loading chart…
Change$-0.09
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.2M | $129.3M | $36.0M | $21.7M | $22.1M | $33.1M | $42.0M | $45.1M |
| Cost of revenue | $6.2M | $86.3M | $80.0M | $37.0M | $24.0M | $27.2M | $29.2M | $32.0M |
| Gross profit | $4.0M | $42.9M | −$44.0M | −$15.2M | −$1.9M | $5.9M | $12.8M | $13.1M |
| Gross margin | 38.9% | 33.2% | -122.1% | -70.2% | -8.7% | 17.7% | 30.5% | 29.1% |
| R&D | $261.0K | $867.0K | $2.2M | $1.4M | $1.0M | $209.0K | $235.0K | $222.8K |
| Operating income | −$8.1M | $6.9M | −$72.6M | −$48.9M | −$29.5M | −$18.3M | −$10.8M | −$8.6M |
| EBITDA | −$7.0M | $9.7M | −$53.4M | −$38.5M | −$25.4M | −$10.5M | −$7.5M | −$7.0M |
| Net income | −$8.4M | $1.1M | −$67.1M | −$54.8M | −$30.0M | −$13.1M | −$10.7M | −$8.3M |
| Net margin | -82.2% | 0.9% | -186.4% | -252.4% | -135.6% | -39.6% | -25.5% | -18.3% |
| EPS (diluted) | -0.12 | 0.01 | -0.48 | -0.22 | -0.11 | -0.04 | -0.03 | -0.02 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $55M | $0.27 | $0.27–$0.27 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
MEDIPHARM LABS CORP
MEDIPHARM LABS CORP
Held by traders on TradeandTell
No one on the platform currently holds MEDIF.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MEDIF as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MEDIF yet.
